Print Page      Close Window     

2018 Press Releases

Keyword Search
 
November 13, 2018
Iovance Biotherapeutics to Participate at November Investor Conferences
SAN CARLOS, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present and participate in the following conferences in November: Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018.   Jefferies Global Healthcare Conference in London, United... More »
November 6, 2018
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its third quarter 2018 financial results and provided a corporate update. “We have made tremendous progress in the last several months. Following our recent end of Phase 2 meeting with the FDA, we released inf... More »
November 6, 2018
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody   Median Duration of Response (DOR) of 6.4 Months   Data selected for oral presentation on Sunday, November 11, 2018 SAN CARLOS, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology,... More »
October 30, 2018
Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018
SAN CARLOS, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2018 financial results on Tuesday, November 6, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference... More »
October 29, 2018
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018
SAN CARLOS, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will host a live webcast of its Melanoma Program Update event for Analysts and Investors on Friday, November 9, 2018 from 6:30 – 8:30pm ET during the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. Iovance’s leaders... More »
October 18, 2018
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
SAN CARLOS, Calif. and GOSSELIES, Belgium , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), today announced that the two companies have entered into a new thr... More »
October 17, 2018
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering
Offering Includes Exercise in Full of the Underwriter’s Option to Purchase an Additional 3.3 Million Shares of Common Stock SAN CARLOS, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 25,300,000 shares of its common stock at a public offering pri... More »
October 12, 2018
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
SAN CARLOS, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and ... More »
October 11, 2018
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
SAN CARLOS, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance. Iovance intends to grant the underwrit... More »
October 11, 2018
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program
—FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor —FDA recommended amending existing ongoing Phase 2 study C-144-01 to add a registration-enabling cohort (Cohort 4) —Cohort 4 enrollment is expected to begin early 2019 with a BLA submission expected in the second half of 2020 —37% objective response rate (ORR) demonstrated in 46 metastat... More »
September 26, 2018
Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Timothy Morris, CFO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:15 p.m. ET in New York, NY. A live audio webcast of the presentation will be available by visiting the Investors section of... More »
August 29, 2018
Iovance Biotherapeutics to Present at Two Investor Conferences in September
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in September: 2018 H.C. Wainwright Annual Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 10:50 a.m. ET   Wells Fargo Securities 2018 Healthcare Conferenc... More »
August 16, 2018
Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center
- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer - - Preliminary Data from Moffitt NSCLC Study to be Presented at the Upcoming 19th World Conference on Lung Cancer in September 2018 - SAN CARLOS, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updates fro... More »
August 6, 2018
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter and six months ended June 30, 2018 financial results and provided a corporate update. “The dosing of the first patient with lifileucel in Europe for the treatment of metastatic melanom... More »
July 30, 2018
Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
SAN CARLOS, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2018 financial and operating results on Monday, August 6, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. In order to participa... More »
June 7, 2018
Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma
SAN CARLOS, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the ongoing C-144-01 Phase 2 trial of LN-144 (lifileucel) for the treatment of patients with metastatic melanoma at a clinical trial site in the United Kingdom.  “The dosing of the first patient with lifileucel in Europe fo... More »
May 31, 2018
Iovance Biotherapeutics to Present at Two Investor Conferences in June
SAN CARLOS, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in June: Jefferies 2018 Global Healthcare Conference in New York, NY on Thursday, June 7, 2018 at 9:00 a.m. ET JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20... More »
May 10, 2018
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its first quarter 2018 financial results and provided a corporate update. “Our January 2018 financing puts us in a strong position to advance and expand our robust TIL product pipeline. We continue enrollm... More »
May 3, 2018
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. In order to participate... More »
May 2, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in May: Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 2:50 p.m. ET UBS Global Healthcare Conference in New York, NY on Monday, May 21, 2018 at... More »
March 12, 2018
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its fourth quarter and year-end 2017 financial results and provided a corporate update. “We ended 2017 having completed significant accomplishments involving both manufacturing and clinical aspects of developm... More »
March 8, 2018
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
SAN CARLOS, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2017 financial and operating results after the close of the U.S. financial markets on Monday, March 12, 2018. Management will host a conference call and live audio webcast to discuss these results and provide ... More »
March 7, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in March: Cowen 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET Oppenheimer’s 28th Annual Healthcare Conference in New York, NY on Wednesday,... More »
March 1, 2018
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
Industry Veteran Brings Significant Clinical, Commercial, and Business Experience SAN CARLOS, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Michael Weiser, M.D., Ph.D., to Iovance’s Board of Directors, effective March 15, 2018.  Dr. Weiser will serve as the chair of Iovance’s Compensation Committee... More »
February 14, 2018
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
SAN CARLOS, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present a corporate overview at the upcoming RBC Capital Markets 2018 Global Healthcare Conference on Thursday, February 22, 2018 at 2:35 p.m. ET in New York, NY. A live audio webcast of the presentation will be available by visiting the... More »
January 29, 2018
Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
SAN CARLOS, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering... More »
January 25, 2018
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
SAN CARLOS, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering... More »
January 24, 2018
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell $125 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance. Iovance intends to grant the underwriters a 30-day option... More »
January 24, 2018
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response                   One of Two Evaluable Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Treated with LN-145 Experienced a Confirmed Partial Response SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer... More »